Publications by authors named "Weiyu Lei"
Article Synopsis
- The EMPA-REG OUTCOME® trial showed that empagliflozin, an SGLT2 inhibitor, is beneficial for cardiovascular health and mortality in type 2 diabetes patients with cardiovascular disease.
- The EMPRISE study analyzed real-world data from patients in Japan, South Korea, and Taiwan, comparing empagliflozin to DPP-4 inhibitors in over 28,700 matched pairs.
- Results indicated that both empagliflozin and SGLT2i significantly reduced the risk of heart failure hospitalization, myocardial infarction, stroke, and all-cause mortality compared to DPP-4i.
Aims/introduction: We investigated the utilization of healthcare resources in patients with type 2 diabetes treated with empagliflozin, a sodium-glucose co-transporter-2 (SGLT2) inhibitor, versus dipeptidyl peptidase-4 (DPP-4) inhibitors in clinical practice in Japan, South Korea, and Taiwan.
Materials And Methods: We analyzed the Japanese Medical Data Vision database (December 2014-April 2018), the South Korean National Health Information Database, and the Taiwanese National Health Insurance claims database (both May 2016-December 2017). Patients with type 2 diabetes starting empagliflozin, 10 or 25 mg, or a DPP-4 inhibitor were matched 1:1 via propensity scores (PS).
Sepiolite-zeolite powder doped with capric acid phase change microcapsules for temperature-humidity control.
J Colloid Interface Sci
August 2021
A composite material with temperature-humidity control functions was prepared by using sepiolite-zeolite powder as humidity control matrix and capric acid phase change microcapsules as temperature control material. The micromorphology, thermal conductivity, compressive strength, hygrothermal effect were studied by environmental scanning electron microscope (ESEM), thermal conductivity test, strength test and hygrothermal effect test, respectively. The results showed that the phase change temperature of capric acid phase change microcapsule is between 31 °C ~ 32 °C, the phase change enthalpy is 123.
View Article and Find Full Text PDFAim: To evaluate the effectiveness of empagliflozin in clinical practice in East Asia in the Empagliflozin Comparative Effectiveness and Safety (EMPRISE) East Asia study.
Materials And Methods: Data were obtained from the Medical Data Vision database (Japan), National Health Insurance Service database (South Korea) and National Health Insurance database (Taiwan). Patients aged ≥ 18 years with type 2 diabetes initiating empagliflozin or a dipeptidyl peptidase-4 (DPP-4) inhibitor were 1:1 propensity score (PS) matched into sequentially built cohorts of new users naïve to both drug classes.
Background: Allergic rhinitis (AR) often coexists with and can significantly worsen bronchial asthma (BA). We evaluated the proportion of patients with BA and concomitant AR (BA+AR) diagnosed and treated in an average clinical practice.
Methods: A cross-sectional study methodology was used to determine the prevalence of AR in patients more than 15 years of age with a documented history of asthma who experienced wheezing during the prior 12 months.